Revolution Medicines, Inc. (RVMD)

NASDAQ: RVMD · IEX Real-Time Price · USD
16.90
1.01 (6.36%)
May 27, 2022 4:00 PM EDT - Market closed
Market Cap1.25B
Revenue (ttm)26.84M
Net Income (ttm)-207.56M
Shares Out74.25M
EPS (ttm)-2.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume580,594
Open15.88
Previous Close15.89
Day's Range15.17 - 16.92
52-Week Range14.08 - 35.07
Beta2.01
AnalystsBuy
Price Target31.82 (+88.3%)
Earnings DateMay 9, 2022

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the...

IndustryBiotechnology
IPO DateFeb 13, 2020
CEOMark Goldsmith
Employees201
Stock ExchangeNASDAQ
Ticker SymbolRVMD
Full Company Profile

Financial Performance

In 2021, RVMD's revenue was $29.39 million, a decrease of -31.62% compared to the previous year's $42.98 million. Losses were -$187.09 million, 73.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is 31.82, which is an increase of 88.28% from the latest price.

Price Target
$31.82
(88.28% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Misses Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 4.88% and 24.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic

2 weeks ago - GlobeNewsWire

7 Stocks That Insiders Are Buying Now. Should You?

Here are seven stocks that have recently seen large amounts of insider purchases: Asana (NYSE:ASAN) Ford (NYSE:F) GameStop (NYSE:GME) Eastman Kodak (NYSE:KODK) Oric Pharmaceuticals (NASDAQ:ORIC) Revolut...

Other symbols:ASANFGMEKODKORICSOFI
1 month ago - InvestorPlace

Insiders Buy More Than $19M Of 3 Stocks

Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view ...

Other symbols:JELDXM
2 months ago - Benzinga

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annu...

Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS Oncogene” Session, as well as Presentations in “Chemistry to the Clinic” and “Challenging T...

2 months ago - GlobeNewsWire

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today ...

2 months ago - GlobeNewsWire

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.23% and 15.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...

2 months ago - Zacks Investment Research

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated

2 months ago - GlobeNewsWire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February...

Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time

3 months ago - GlobeNewsWire

Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today a...

3 months ago - GlobeNewsWire

Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentati...

RAS(ON) Inhibitor Pipeline Expands with Advancement of Two New Drug Candidates; Development-Stage Portfolio Covers RAS Drivers of Majority of RAS-Addicted Cancers

4 months ago - GlobeNewsWire

Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier ta...

6 months ago - GlobeNewsWire

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -16.13% and -88.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...

6 months ago - Zacks Investment Research

Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier ta...

6 months ago - GlobeNewsWire

Earnings Preview: Revolution Medicines, Inc. (RVMD) Q3 Earnings Expected to Decline

Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021

Conference Call and Webcast Scheduled for Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time

6 months ago - GlobeNewsWire

Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual Intern...

Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session

7 months ago - GlobeNewsWire

Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit

Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs

8 months ago - GlobeNewsWire

Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier t...

8 months ago - GlobeNewsWire

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.09% and -19.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Revolution Medicines: Q2 Earnings Insights

Shares of Revolution Medicines (NASDAQ:RVMD) fell 8.0% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 30.43% year over year to ($0.60), whi...

9 months ago - Benzinga

Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress

Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic

9 months ago - GlobeNewsWire

Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021

Conference Call and Webcast Scheduled for Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time

9 months ago - GlobeNewsWire

Earnings Preview: Revolution Medicines, Inc. (RVMD) Q2 Earnings Expected to Decline

Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeti...

Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company's First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor Findings Published in Nature Chemica...

11 months ago - GlobeNewsWire